Fluticasone propionate, the active ingredient in Flonase and several inhaled asthma medications, is generally considered low-risk during pregnancy. No increased rate of birth defects has been found in studies of pregnant women who used it, and the drug enters the bloodstream in extremely small amounts when used as a nasal spray. That said, formal FDA labeling states there is insufficient data to fully define the risk, which is why the question comes up so often.
Why Systemic Absorption Matters
The reason fluticasone propionate is considered relatively safe comes down to how little of it actually reaches your bloodstream. When you use the nasal spray, only about 0.5% of the dose is absorbed systemically. For nasal drops, it’s even lower at roughly 0.06%. Compare that to some other nasal corticosteroids: triamcinolone acetonide and beclomethasone dipropionate each have systemic bioavailability around 44%, and budesonide sits at about 31%.
This extremely low absorption means the amount of fluticasone circulating in your body after a spray or two is negligible. For a drug to affect a developing fetus, it typically needs to reach meaningful levels in the bloodstream first. With fluticasone propionate nasal spray, those levels are barely detectable.
What the Studies Show About Birth Defects
A UK population-based cohort study specifically examined fluticasone propionate prescribed for asthma during pregnancy. The absolute risk of a major congenital malformation after first-trimester exposure was 2.4% for women on moderate treatment and 2.7% for those on more intensive treatment. For context, the baseline rate of major birth defects in the general population is roughly 2% to 3%, meaning these numbers fall within the normal expected range.
When researchers compared women using fluticasone propionate to those using other inhaled corticosteroids, the adjusted odds ratios were 1.1 and 1.2 for moderate and higher intensity use, respectively. Neither result was statistically significant, which means no meaningful difference in risk was detected between fluticasone and other inhaled steroids. The results were similar whether women used fluticasone alone or in combination products.
First Trimester Use
The first trimester is the period of greatest concern for any medication because that’s when major organ systems form. Between 23% and 36% of women stop using their inhaled corticosteroids during the first or second trimester out of safety concerns. But the evidence doesn’t support stopping.
A large Canadian cohort study of over 4,300 women confirmed the safety of low to moderate doses of inhaled corticosteroids during the first trimester. Research reviews covering multiple studies have reached the same conclusion: continuing these medications throughout pregnancy at the lowest effective dose is the recommended approach.
The Risk of Stopping Treatment
Discontinuing fluticasone propionate during pregnancy carries its own risks, particularly for women using it to manage asthma. One study found that women who experienced an asthma exacerbation during the first trimester had an increased risk of congenital malformations, with an odds ratio of 1.48. In other words, uncontrolled asthma itself poses a greater threat to the pregnancy than the medication used to treat it.
A Danish study tracking 108 pregnant women on inhaled corticosteroids found that the roughly 20% who discontinued or reduced their medication gave birth to babies with lower birth weight and shorter birth length compared to women who maintained their treatment. Poor asthma control reduces oxygen delivery to the fetus and increases stress hormones, both of which can affect fetal growth.
For allergic rhinitis, the stakes are lower than for asthma, but chronic nasal congestion can disrupt sleep, reduce quality of life, and in some cases contribute to mouth breathing and poor rest, none of which help a healthy pregnancy.
Safety During Breastfeeding
No measurable levels of fluticasone propionate have been detected in breast milk, and no studies have found effects on breastfed infants. Given how little of the drug reaches the bloodstream in the first place, the amount that could transfer into milk is considered too small to be clinically relevant. Expert panels, including those behind the LactMed database maintained by the National Institutes of Health, consider inhaled and nasal corticosteroids acceptable during breastfeeding.
Nasal Spray vs. Inhaler
Most people searching this question are using fluticasone propionate as a nasal spray for allergies. The nasal spray delivers a small, localized dose with that very low 0.5% systemic absorption. Inhaled forms used for asthma deliver slightly higher doses to the lungs, where absorption can be somewhat greater, but the overall systemic exposure remains low compared to oral corticosteroids like prednisone.
If you’re using the nasal spray for seasonal or year-round allergies, you’re getting the lowest possible systemic exposure of any fluticasone delivery method. The inhaled version for asthma has a slightly different profile but is still supported by the safety data described above. Oral corticosteroids, by contrast, have much higher systemic levels and a more complex risk profile during pregnancy.
What the FDA Label Actually Says
The current FDA labeling for Flonase states that there is “insufficient data” to define a drug-associated risk during pregnancy. This sounds more alarming than it is. The FDA requires large, controlled human trials to make definitive safety claims, and for ethical reasons, those trials are rarely conducted in pregnant women. The “insufficient data” label applies to many medications that have been used safely in pregnancy for decades. It reflects a gap in a specific type of evidence, not a known danger.
The observational studies that do exist, involving thousands of pregnancies, have not identified increased risks. Professional guidelines from organizations focused on allergy and respiratory medicine consistently recommend continuing fluticasone propionate when it’s needed to control symptoms during pregnancy.